Seretide 250 Evohaler

Seretide (marketed as Advair in some regions) is a prominent combination medication used for the long-term management of asthma and COPD. It was originally developed and launched by Glaxo Wellcome, which merged with SmithKline Beecham to form the global healthcare giant GSK. The medication contains salmeterol and fluticasone propionate, delivered via the 'Evohaler' pressurized metered-dose inhaler system.

The product's manufacturing is centralized in large-scale pharmaceutical facilities, with the site in Evreux, France, being one of the primary global hubs for GSK’s respiratory portfolio. As a highly regulated medical product, ownership remains strictly with GSK, which operates as one of the world's leading research-based pharmaceutical and healthcare companies. The packaging shown features a pharmacy label from Ireland, indicating its legal distribution in the European market through local healthcare channels.